Enantigen Therapeutics Inc is categorized under Research and Development Laboratories in Doylestown, PA and active since 2008.
Enantigen Therapeutics Inc was established in 2008, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Research and Development Laboratories business, which does work in the B2B market, and is classified as a Research and Development Laboratories, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Xiaodong Xu at the company’s single location by writing to 3805 Old Easton Road, Doylestown, Pennsylvania PA 18902 or by phoning (215) 589-6315. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Enantigen Therapeutics Inc |
| Contact Person: | Xiaodong Xu |
| Address: | 3805 Old Easton Road, Doylestown, Pennsylvania 18902 |
| Phone Number: | (215) 589-6315 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2008 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Research and Development Laboratories |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Enantigen Therapeutics Inc was started in 2008 to provide professional Research and Development Laboratories under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Xiaodong Xu for inquiries that concern Enantigen Therapeutics Inc by calling the company number (215) 589-6315, as your correspondence is most welcome. Additionally, the physical location of the single location of Enantigen Therapeutics Inc can be found at the coordinates 40.333189,-75.12617 as well as the street address 3805 Old Easton Road in Doylestown, Pennsylvania 18902.
For its online presence, you may visit Enantigen Therapeutics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.